Hypoactive Sexual Desire Disorder (HSDD) Clinical Trial
Official title:
Acupuncture in Premenopausal Women With Hypoactive Sexual Desire Disorder: A Prospective Cohort
Verified date | February 2014 |
Source | TriHealth Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Female Sexual Dysfunction (FSD) affects up to 43% of women in the United States and Hypoactive Sexual Desire Disorder (HSDD) is the most common form. There is no standardized treatment for this condition. We know that alternative therapies such as acupuncture have been beneficial to women suffering from urinary incontinence, chronic lower back pain, and migraines. We hypothesize that the quality of life for premenopausal women with hypoactive sexual desire disorder (HSDD) will improve with initiation of acupuncture therapy for a duration of 5-weeks. Validated questionnaires are administered at the time of enrollment and 1 week after the final acupuncture session as the method of analyzing our primary outcome.
Status | Completed |
Enrollment | 15 |
Est. completion date | June 2014 |
Est. primary completion date | June 2014 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Women aged 18-55 years - Sexually Active - Premenopausal - Documented diagnosis of HSDD as primary cause of FSD (defined as a non adjusted score of = 6 in the desire domain of the FSFI questionnaire) Exclusion Criteria: - Postmenopausal, defined as absence of menstruation in the prior 12 months - Pain or dyspareunia as the primary cause of FSD (defined as a non adjusted score of = 6 in the pain domain of the FSFI) - History of hysterectomy and/or oophorectomy - History of chemotherapy, or pelvic irradiation - Use of hormonal contraception or oral hormone replacement therapy - Active skin infection or disease - Blood dyscrasia - Allergy to acupuncture needles |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | TriHealth | Cincinnati | Ohio |
Lead Sponsor | Collaborator |
---|---|
TriHealth Inc. | TriHealth Medical Education Research Fund |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Female Sexual Function Index (FSFI) | Determined by a change in the desire domain of the Female Sexual Function Index (FSFI) from baseline at enrollment to study completion at 6 weeks after initiation of intervention. | 6 weeks | No |
Secondary | Female Sexual Distress Scale (FSDS-R) | Determined by functional data points distributed at enrollment and 6 weeks: Female Sexual Distress scale - revised (FSDS-R) |
6 weeks | No |
Secondary | Short Form-12 (SF-12) | Determined by functional data points distributed at enrollment and 6 weeks: Short Form-12 (SF-12) |
6 weeks | No |
Secondary | Generalized Anxiety-Disorder-7 (GAD-7) and Prime Health Questionnaire-9 (PHQ-9) | Determined by functional data points distributed at enrollment and 6 weeks: Generalized Anxiety-Disorder-7 (GAD-7) and Prime Health Questionnaire-9 (PHQ-9) |
6 weeks | No |
Secondary | World Health Organization Quality of Life- BREF (WHOQOL) | Determined by functional data points distributed at enrollment and 6 weeks: World Health Organization Quality of Life- BREF (WHOQOL) |
6 weeks | No |
Secondary | Patient Global Impression of Improvement (PGI-I) | Determined by functional data points distributed at enrollment and 6 weeks: Patient Global Impression of Improvement (PGI-I) |
6 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03619005 -
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study
|
Phase 3 | |
Completed |
NCT03080298 -
Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire
|
Phase 2 | |
Completed |
NCT00349791 -
Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
|
Phase 3 | |
Completed |
NCT01702818 -
Stress Hormones, Mood and Women's Sexual Desire (MODEST)
|